Durvalumab vs Gefitinib

Durvalumab vs Gefitinib: Overview

This comparison examines the pharmacological differences between Durvalumab and Gefitinib.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Gefitinib: Selective reversible inhibitor of EGFR tyrosine kinase.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Gefitinib — 48 hours.

Chemical Properties

Molecular Formula: Gefitinib — C22H24ClFN4O3.

Molecular Weight: Gefitinib — 446.9000 g/mol.

Type: Durvalumab — Antibody; Gefitinib — Small molecule.